Conference - Events
Featured Events
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston for the third year bringing together the top industry players developing individualized approaches across several modalities including mRNA, DNA, peptides, viral, dendritic cell and more to share how they are conquering common challenges, developing novel bioinformatic strategies, and achieving clinical efficacy.
Join the likes of BioNTech, CureVac, Imvax, NousCom and 80+ key stakeholders at th…
As the cell and gene therapy landscape advances, underscored by recent approvals from leaders like Bristol Myers Squibb and Orchard Therapeutics, the role of medical affairs professionals is becoming increasingly indispensable. They bridge the gap between industry and the medical community, united in their mission to enhance patient outcomes.
Introducing the Cell & Gene Therapy Medical Affairs Summit, the premier event highlighting the essential role of medical affairs in delivering therapies to patients. Explore how traditional approaches are being revolutionized to tackle the unique challenges of cell and gene therapy drug development. Here, the fusion of scientific and clinical expertise with strategic commercial vision creates opportunities for transformative breakthroughs!
Whether…
With 5% of cancer drugs going into the clinic, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery, particularly with such a high price tag for clinical failure.
The 13th Tumour Models London Summit stands as the only industry-led meeting uniting pharma, biotech, and preclinical CROs from Europe to network and discuss new trends and innovations in tumour models. Attracting leading preclinical and translational expertise, this forum provides an essential platform for scientists and decision makers to hear about the latest innovations in in vivo and in vitro tumour modelling to de-risk their studies and accelerate their product's journey from lab to…
Events
Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. In 2024, a wave of collaborations has surged, propelling the use of liquid biopsies for MRD testing to new heights. The FDA's recognition of MRD as an endpoint in multiple myeloma marks a monumental leap forward for the field, heralding a new era in patient care and therapeutic development.
The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision…
The marcus evans 15th Edition Strategic Alliance Management for Pharma conference taking place on 25-27 November, 2024, in Berlin, Germany, will bring together key industry experts to benchmark best practices on how to build innovative capabilities and strategies that will help build durable alliances, create effective performance measurement framework and ensure a solid governance structure that will not only drive portfolio value but also have the right means for efficient risk mitigation process.
Attending This Premier marcus evans Conference Will Enable You to:
Establish Effective Governance and Decision-making Process within the Alliance.
Navigating Data Management from Deal to Alliance.
Competence Development: A Combined Business Development and Alliance Management Practice.
Navigat…
Unlocking Previously Inaccessible GPCR Drug Targets
As structural biology tools and screening technologies advance, the GPCR super family continues to be a hot area of drug discovery, with the potential to treat a plethora of diseases. For the first time ever, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London, with the aim of overcoming pharmacology challenges and advancing the next wave of GPCR drug discovery.
This November, leading European biopharma experts and trail-blazing opinion leaders of academia are uniting under one roof at this inaugural Meeting to share data, discuss the latest advances in drug discovery. This Summit will deconvolute signalling bias, reveal novel targets for successful therapeutic interventions and fast-track structurally guided GPCR drug dis…
The Pharmaceutical and Medical Meeting Planners' Summit brings together meeting management professionals from the pharma, life sciences, medical, and healthcare industries who are dedicated to designing and executing customer-focused events while complying with state, national, and global regulations.
Medical meeting planners are constantly grappling with issues including budgeting, hotel contract negotiation, vendor management, audience engagement, travel restrictions, burnout, and more.
The global economic crisis, inflation, and workforce shortages have forced planners to think differently, pivot, and adopt novel approaches to efficiently execute meetings without compromising on quality and experience. At this year's event, attendees explore strategies to break away from the status quo,…
Welcome to the 2nd Cell Therapy for Autoimmune Disease Summit
Following the latest data revealing the promise of cell therapies for lupus, all eyes are on how to pave the way to develop the first curative treatments for autoimmune patients
The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year's explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. This is your unmissable opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication.
Join 30+ trailblazers including Cartesian Therapeutics, Bristol Myers Squibb, the University of Pennsylvania, ImmPACT Bio and more as they unveil their latest clinica…
CNS drug development is facing a new era, thanks to huge strides in neuroscience innovation, including advances in blood-brain barrier transport, CSF administration, and device-mediated delivery, to solve the field's most pressing challenge: access to the brain.
Riding the wave of drug delivery innovation, the industry's definitive 6th CNS Drug Delivery Summit returns to showcase breakthrough progress in receptor-mediated transcytosis, CSF dose escalation, quantifying brain distribution, BBB modeling, CED and FUS technology, emerging modalities including LNPs, and more.
Join 100+ of your industry colleagues from the likes of Roche, Biogen, UCB, JCR, Ionis, Denali, Eli Lilly, Alector, Novartis, Bristol Myers Squibb, Sanofi, and Takeda as they seek to discover and translate safer, more effec…
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston for the third year bringing together the top industry players developing individualized approaches across several modalities including mRNA, DNA, peptides, viral, dendritic cell and more to share how they are conquering common challenges, developing novel bioinformatic strategies, and achieving clinical efficacy.
Join the likes of BioNTech, CureVac, Imvax, NousCom and 80+ key stakeholders at th…
Demonstrating your cell therapy's superior safety and efficacy is vital for standing out in a competitive market and attracting investment. Integrating cutting-edge technologies and robust analytical methods is key to showcasing your product's strengths and securing regulatory approval.
Join the 6th Cell Therapy Analytical Development Summit to advance your analytics, accelerate through IND and clinical trials, and achieve regulatory success.
Explore three focused tracks on immunophenotype, cell-based, and molecular assays. Collaborate with industry leaders like Bristol Myers Squibb, Kite Pharma, and Takeda, and gain actionable insights to propel your pipeline forward.
Engage with experts to overcome challenges in product characterization, method validation, release, and scale-up.
To…
The 5th Genome Editing Therapeutics Summit (formerly CRISPR 2.0) is the industry's foremost meeting for spearheading the development, application, and delivery of novel gene editing technologies in the therapeutic setting. Data-driven talks, expert panel discussions, and interactive group discussions will cover the therapeutic application and drug development challenges of both:
1. More established technologies, and their associated translational, nonclinical, clinical, and strategic challenges: including novel nucleases, base, prime, and multiplex editing techniques
2. Ground-breaking precision tools enabling small and large alterations to the genome, including epigenome editing, recombinase and transposon-based technologies, and novel delivery vehicles
Across three days, industry a…
As the cell and gene therapy landscape advances, underscored by recent approvals from leaders like Bristol Myers Squibb and Orchard Therapeutics, the role of medical affairs professionals is becoming increasingly indispensable. They bridge the gap between industry and the medical community, united in their mission to enhance patient outcomes.
Introducing the Cell & Gene Therapy Medical Affairs Summit, the premier event highlighting the essential role of medical affairs in delivering therapies to patients. Explore how traditional approaches are being revolutionized to tackle the unique challenges of cell and gene therapy drug development. Here, the fusion of scientific and clinical expertise with strategic commercial vision creates opportunities for transformative breakthroughs!
Whether…
With 5% of cancer drugs going into the clinic, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery, particularly with such a high price tag for clinical failure.
The 13th Tumour Models London Summit stands as the only industry-led meeting uniting pharma, biotech, and preclinical CROs from Europe to network and discuss new trends and innovations in tumour models. Attracting leading preclinical and translational expertise, this forum provides an essential platform for scientists and decision makers to hear about the latest innovations in in vivo and in vitro tumour modelling to de-risk their studies and accelerate their product's journey from lab to…
Join 80+ CapEx, Construction and Engineering professionals from leading pharma, biotech, CDMO and medtech companies across to the United Stated to tackle the following issues head on:- Optimizing risk management- Enhancing supply chain collaboration- Scaling real estate portfolios- Rising demands for new manufacturing facilitiesDiscover the best strategies, learn from industry achievements and gain a practical guide to creating cutting-edge, sustainable and innovative facilities-ensuring cost efficiency and faster speed to market.
URLs:Tickets: https://go.evvnt.com/2674381-2?pid=185Brochure: https://go.evvnt.com/2674381-3?pid=185
Time: 9:00 AM - 4:30 PM
Speakers: Josh Ames, Associate Director, Moderna, Julie Almeida, Director, Capital Projects Management, Ultragenyx, Aimee Monegro, Capital…
The 10th Winter Process Conference will showcase presentations from International Chemists covering all aspects of Process Development.
The speakers will discuss the latest issues in synthetic route design, development and optimisation, reactor design, work up and purification, crystallisation, process engineering, hazard studies and quality and regulatory issues.
The presentations will be either from speakers within the chemical industry or academics with a strong link to industrial process development so the material presented with be of particular relevance to all chemists and engineers in industry as well as graduate students considering a career in industry.
YOUNG CHEMIST AWARD
Scientific Update are inviting 2nd , 3rd or 4th year PhD students to present their work at the above confere…
With the applications of LNPs rapidly expanding beyond vaccines, as well as beyond the liver, it is of utmost importance to predict and minimize adverse reactions to guarantee patient safety in the clinic, especially following a clinical hold on Verve Therapeutics' gene therapy earlier this year, due to safety concerns surrounding the LNP delivery system.
Returning in December, the 3rd LNP Immunogenicity and Toxicity Summit will return as your unique forum uniting industry experts striving to measure, predict and monitor non-clinical and clinical safety risk for lipid nanoparticles to ensure regulatory compliance for vaccines, gene and cell therapies.
Join experts from Pfizer, AstraZeneca, Moderna, BioNTech and Beam Therapeutics, as they dive deep into mechanisms of toxicity, optimal deliv…
Welcome to the 4th ADC Target Selection Summit! Get the First Most Important Decision Right.
The ADC field continues to grow, saturating the industry and demanding continuous innovation to leave your work in the field. For this reason, biopharma and biotech are shifting attention to advanced target selection methods to source novel routes for ADC therapeutic activity.
The 4th ADC Target Selection Summit has been created for those professionals seeking to develop a first-in-class ADC through innovation in the target.
From honing into the complex mechanistic biology around the target to implementing advanced computational approaches to screen potential targets, don't miss this opportunity to place novel targeting as a high priority.
Date and Time: Tuesday, 10 December 2024 at 08:00 to Thursd…
With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space.
In the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients, the 4th Rare and Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry, academic KOL, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations.
This year's meeting brings together 30+ expert speakers, a two-tracked pre-conference workshop day and ne…
Welcome to a pivotal moment in the Golden Age of Biocatalysis, where industry leaders like Eli Lilly and Pfizer are transforming small molecule operations and biopharma is pushing the boundaries of biologics development. This year, we're witnessing ground breaking advancements as biocatalysis becomes central to biologics and therapeutic innovation.
In collaboration with Merck, Novo Nordisk and Pfizer, we're excited to bring you the 4th Applied Biocatalysis and Enzyme Engineering Summit - now with a sharper focus on enzyme engineering and expanded coverage of biocatalysis-derived oligonucleotides, peptides and other large biologics. Plus, dive into brand-new biopharma case studies designed to boost enzyme efficiency and therapeutic yields.
Why Attend?
- Revolutionize Biologics Development:…
As biopharmaceutical pipelines expand with increasingly complex modalities at a faster rate than ever, the landscape for EHS leaders is rapidly evolving.
Navigating the complexities of compliance regulations while safeguarding your workforce has never been more critical. With an increasing number of R and D and manufacturing facilities across large pharma, biotech, CDMOs, and CROs, handling potentially hazardous chemical and biological materials, the demand for robust biosafety, ergonomic, chemical, and environmental protocols is at an all-time high.
You'll have the unique chance to network with a focused group of EHS leaders from Genentech, Eli Lilly, Takeda and more as they share high-level strategies and practical, day-to-day solutions. You'll be in the company of over 60 global d…
Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors
The complement community is shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted.
With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field has everyone asking the same question: which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?
From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape is primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.
Joi…
With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins and RNA/protein complexes.
Hence, as the go-to meeting for the RNA-targeting small molecule the community, the 7th Annual RNA-Targeted Drug Discovery and Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures, delve into innovative preclinical modelling strategies and identify optimal chemical features for advancing specific, efficacious and safe small molecules.
Unite with 100+ RNA Science, Medicinal Chemistry, Structural Biology and Biophysics experts from the likes of Astra…
